{"id":"amoxicillin-or-moxifloxacin","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Nausea"},{"rate":"5-10%","effect":"Vomiting"}]},"_chembl":{"chemblId":"CHEMBL1200735","moleculeType":"Small molecule","molecularWeight":"437.90"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This results in the disruption of the bacterial cell wall, ultimately leading to cell lysis and death. Amoxicillin is a broad-spectrum antibiotic, effective against a wide range of Gram-positive and Gram-negative bacteria.","oneSentence":"Amoxicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:44:28.568Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Uncomplicated urinary tract infections"},{"name":"Acute bacterial otitis media"},{"name":"Community-acquired pneumonia"}]},"trialDetails":[{"nctId":"NCT07485010","phase":"PHASE2","title":"Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial","status":"NOT_YET_RECRUITING","sponsor":"The University of Queensland","startDate":"2027-04","conditions":"Mycobacterium Abscessus Pulmonary Disease, Mycobacterium Abscessus Infection, Non-Tuberculous Mycobacterial (NTM) Infections","enrollment":300},{"nctId":"NCT05398679","phase":"PHASE4","title":"Oral Antimicrobial Treatment vs. Outpatient Parenteral for Infective Endocarditis","status":"RECRUITING","sponsor":"Fundacion Clinic per a la Recerca Biomédica","startDate":"2022-08-17","conditions":"Endocarditis Infective","enrollment":360},{"nctId":"NCT06537609","phase":"NA","title":"A Platform Trial for Gram Negative Bloodstream Infections","status":"RECRUITING","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2024-04-24","conditions":"Gram-negative Bacteremia","enrollment":2500},{"nctId":"NCT06294600","phase":"PHASE3","title":"Clarithromycin Treatment to Prevent Sepsis Progression in CAP (REACT)","status":"RECRUITING","sponsor":"Hellenic Institute for the Study of Sepsis","startDate":"2024-02-12","conditions":"Community-acquired Pneumonia","enrollment":330},{"nctId":"NCT05977868","phase":"PHASE4","title":"Comparing Oral Versus Parenteral Antimicrobial Therapy","status":"TERMINATED","sponsor":"West Virginia University","startDate":"2023-08-04","conditions":"Endovascular Infection, Bone and Joint Infection, Skin and Soft Tissue Infection","enrollment":94},{"nctId":"NCT06423898","phase":"PHASE4","title":"Ampicillin and Ceftriaxone for the Treatment of Enterococcus Faecalis Infective Endocarditis.","status":"RECRUITING","sponsor":"Fundación Pública Andaluza para la gestión de la Investigación en Sevilla","startDate":"2024-10-09","conditions":"Endocarditis, Infective","enrollment":284},{"nctId":"NCT03479736","phase":"","title":"A Study of Fluoroquinolones Exposure and Collagen-Related Serious Adverse Events","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2017-11-20","conditions":"Retinal Detachment, Achilles Tendon, Aneurysm, Dissecting","enrollment":117911},{"nctId":"NCT05893147","phase":"NA","title":"BALANCE+ Vanguard Phase","status":"COMPLETED","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2023-08-26","conditions":"Gram-negative Bacteremia","enrollment":174},{"nctId":"NCT02735707","phase":"PHASE3","title":"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia","status":"RECRUITING","sponsor":"UMC Utrecht","startDate":"2016-04-11","conditions":"Community-acquired Pneumonia, Influenza, COVID-19","enrollment":20000},{"nctId":"NCT05902221","phase":"PHASE3","title":"Impact of Rifampicin in Treatment Outcome of Cutibacterium Acnes Prosthetic Joint Infections","status":"NOT_YET_RECRUITING","sponsor":"Centre Hospitalier Universitaire de Nice","startDate":"2024-03-30","conditions":"Infections Joint Prosthetic","enrollment":235},{"nctId":"NCT02373280","phase":"NA","title":"The Efficacy of the 7 Days Tailored Therapy as the 1st Eradication of H. Pylori Infection","status":"UNKNOWN","sponsor":"Seoul National University Bundang Hospital","startDate":"2014-08","conditions":"Helicobacter Infection","enrollment":600},{"nctId":"NCT02099240","phase":"EARLY_PHASE1","title":"Patients Response to Early Switch To Oral:Osteomyelitis Study","status":"TERMINATED","sponsor":"Julio Ramirez","startDate":"2014-03-06","conditions":"Osteomyelitis","enrollment":11},{"nctId":"NCT03625739","phase":"","title":"Population Pharmacokinetics of Anti-tuberculosis Drugs in Children With Tuberculosis","status":"RECRUITING","sponsor":"Beijing Children's Hospital","startDate":"2018-07-01","conditions":"Tuberculosis","enrollment":800},{"nctId":"NCT01069900","phase":"PHASE3","title":"Moxifloxacin in Pediatric Subjects With Complicated Intra-abdominal Infection","status":"COMPLETED","sponsor":"Bayer","startDate":"2010-07-21","conditions":"Intraabdominal Infections","enrollment":458},{"nctId":"NCT02349685","phase":"NA","title":"The Efficacy of the Tailored Therapy Based on Antimicrobial Susceptibility for 2nd Eradication of H. Pylori","status":"COMPLETED","sponsor":"Seoul National University Bundang Hospital","startDate":"2010-01","conditions":"Helicobacter Infection","enrollment":219},{"nctId":"NCT01434173","phase":"","title":"Risk of Acute Liver Injury in Users of Antimicrobials","status":"COMPLETED","sponsor":"Bayer","startDate":"2001-07","conditions":"Drug-Induced Liver Injury","enrollment":1299056},{"nctId":"NCT00531791","phase":"PHASE3","title":"Effects of Advair® in Outpatients With Chronic Obstructive Pulmonary Disease (COPD) Acute Exacerbation","status":"COMPLETED","sponsor":"Laval University","startDate":"2007-11","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":14}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":34293,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"amoxicillin or moxifloxacin","genericName":"amoxicillin or moxifloxacin","companyName":"Centre Hospitalier Universitaire de Nice","companyId":"centre-hospitalier-universitaire-de-nice","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Amoxicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins. Used for Uncomplicated urinary tract infections, Acute bacterial otitis media, Community-acquired pneumonia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}